New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
07:04 EDTALKSAlkermes announces phase 3 'positive' results from aripiprazole lauroxil study
Alkermes announced "positive" topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale total scores at week 12, compared to placebo, which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application to the U.S. Food and Drug Administration in 3Q14. In addition to meeting the prespecified primary efficacy endpoint, the study also met the prespecified key secondary endpoint of improvement on the Clinical Global Impression-Improvement scale versus placebo at week 12. Aripiprazole lauroxil was generally well tolerated in the phase 3 study, and the safety profile of aripiprazole lauroxil was similar to that reported with oral aripiprazole. The most common adverse events in the study were insomnia, akathisia and headache. Alkermes will present data from the phase 3 study at an upcoming medical meeting and submit the results for publication in a peer-reviewed journal.
News For ALKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
07:16 EDTALKSCowen to hold a conference
35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 3 at 8 am; not all company presentations may be webcasted. Webcast Link
06:27 EDTALKSAlkermes fundamentally well positioned, says JPMorgan
Subscribe for More Information
March 2, 2015
08:11 EDTALKSAlkermes to hold an analyst and investor meeting
Subscribe for More Information
07:03 EDTALKSAlkermes reports new drug candidate for treatment of depression, other diseases
Subscribe for More Information
February 25, 2015
08:30 EDTALKSAlkermes price target raised to $79 from $75 at Leerink
Leerink raised its price target for Alkermes shares to $79 to reflect probability-of-success weighted ALKS 8700 in multiple sclerosis revenue. The firm views the company's Q4 results as strong, but notes its 2015 outlook missed consensus due to higher than expected operating expenses. Leerink says the 2015 guidance reflects Alkermes' maturing pipeline. It keeps an Outperform rating on the stock.
06:19 EDTALKSAlkermes pipeline eases loss of pain program, says Citigroup
Citigroup says Alkermes' pipeline programs and the continued growth of its base business help moderate the disappointment of the discontinuation of novel pain program ALKS-7106. Citi lowered its price target for Alkermes shares to $83 from $85 and keeps a Buy rating on the stock.
05:57 EDTALKSUBS says remain on sidelines with respect to Alkermes
Subscribe for More Information
February 24, 2015
10:06 EDTALKSHigh option volume stocks
High option volume stocks: CHGG LBTYK SMH RCAP NGLS OTEX TERP CNC ALKS AMT
08:56 EDTALKSOn The Fly: Pre-market Movers
Subscribe for More Information
08:54 EDTALKSAlkermes 7106 halt overshadows Q4 beat, says Credit Suisse
Subscribe for More Information
07:06 EDTALKSAlkermes sees FY15 adjusted EPS 27c-40c, consensus 20c
Subscribe for More Information
07:03 EDTALKSAlkermes reports Q4 EPS 11c, consensus 4c
Subscribe for More Information
07:01 EDTALKSAlkermes announces phase 1 results for ALKS 7106, will not proceed to phase 2
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use